Form 4: Cullinan CFO Boosts Stake with New Equity Awards

Cullinan Therapeutics' Chief Financial Officer, Mary Kay Fenton, acquired 68,750 restricted stock units and 137,500 stock options as part of her compensation.

Summary

• Mary Kay Fenton, Chief Financial Officer of Cullinan Therapeutics, Inc. (CGEM), reported an acquisition of equity securities.
• On February 18, 2026, Fenton acquired 68,750 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs will vest on an annual basis over four years.
• Additionally, on February 18, 2026, Fenton acquired 137,500 Stock Options with an exercise price of $12.44.
• The stock options will vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.
• Following these transactions, Fenton beneficially owns 130,778 shares of Common Stock and 137,500 Stock Options directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management's interests with shareholders, without indicating any immediate operational or financial changes.

Positives

• The acquisition of restricted stock units and stock options aligns the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance.
• Equity awards are a standard component of executive compensation, indicating continued commitment to retaining key management.

Future Outlook

The filing details vesting schedules for the acquired equity, indicating future milestones for the Chief Financial Officer's beneficial ownership. The restricted stock units will vest annually over four years, and the stock options will vest monthly over four years.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and stock options to executive officers is a common practice in the biotechnology and pharmaceutical industries. This form of compensation is designed to attract and retain talent, while also aligning management's financial incentives with the long-term success and shareholder value creation of the company.

Stakeholder Impact

• Shareholders: The equity awards align the Chief Financial Officer's financial interests with shareholder value creation over the long term.
• Employees: This transaction reflects standard executive compensation practices, which can influence overall compensation strategies within the company.

Next Steps

• Vesting of 68,750 restricted stock units annually over four years from February 18, 2026.
• Vesting of 137,500 stock options in equal monthly installments (1/48th) over four years from February 18, 2026.

Key Dates

Keywords

Cullinan Therapeutics, CGEM, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Equity Awards